Promising Growth Forecasts Leading to Analysts’ Optimism for Procept Biorobotics (PRCT)

Core Viewpoint - Procept Biorobotics Corp. (NASDAQ:PRCT) is identified as a promising mid-cap healthcare stock with significant upside potential, supported by bullish analyst ratings and growth prospects [1][3]. Group 1: Analyst Ratings and Price Targets - UBS analyst Danielle Antalffy initiated coverage with a Buy rating and a target price of $62, indicating an upside potential of over 93% from current levels [1][2]. - As of December 19, 80% of 10 analyst ratings for the stock were Buy calls, with a 1-year average price target of $51.75, suggesting over 61% upside potential [3]. Group 2: Company Overview and Growth Prospects - Procept Biorobotics Corp. specializes in surgical robotics, focusing on robotic treatments for male urological health, particularly through its flagship Aquablation® therapy [4]. - The company aims to increase the utilization of its current installed base and expand into new markets, with expectations of turning profitable by 2027 due to revenue growth, improved gross margins, and operational efficiencies [2].